How violence in Israel and Palestine is impacting COVID-19 rates

As many Americans who lived through wildfire season, hurricane season, or the Texas winter storm know well: it’s hard to protect yourself in a pandemic when you’re dealing with another simultaneous disaster.

And it is especially hard to protect yourself when you live in a region that’s cut off from resources and medical expertise—as is the case for people in Gaza and other Palestinian territories.

In the past couple of weeks, violence in this region has shut down hospitals and prevented vaccine deliveries. Unvaccinated people have crowded into shelters in Gaza, while all testing and vaccination efforts have stalled.

Gaza has also lost critical medical leadership in the recent violence: two senior doctors at  Al-Shifa Hospital, the largest hospital in the Gaza Strip, were killed in recent Israeli airstrikes. An early-morning attack on the al-Wehda district last Sunday killed Dr. Ayman Abu al-Ouf, head of internal medicine at the hospital, and Dr. Mooein Ahmad al-Aloul, a psychiatric neurologist, along with at least 30 others.

Al Jazeera reports that “medical personnel remain in short supply” throughout the Palestinian territories, leaving people to instead rely on international aid groups for medical care. And constant air raids have limited medical care even further. One Israeli attack blocked the main road leading to Al-Shifa hospital, for example, and a Doctors Without Borders clinic was hit last weekend.

“People are not daring to visit health facilities. We are fearing this will have a major negative impact,” Sacha Bootsma, an official from the World Health Organization, told the New York Times.

About 5% of Palestinians have been vaccinated as of May 20. Most of those doses have come from COVAX, the global vaccine alliance, and shipments have faced logistical challenges in getting to Gaza through an Israeli blockade. The United Nations released a statement in January calling on Israel to “ensure swift and equitable access to COVID-19 vaccines for the Palestinian people under occupation,” but Israeli leaders have denied this responsibility.

Israel, meanwhile, is largely protected against a COVID-19 surge. The country has been a global leader in vaccinations; by the end of February, over half of the population had received at least one dose. Now, almost two-thirds of the population are vaccinated.

Cases in Israel have remained at low levels throughout the violence in recent weeks thanks to the vaccines. The country has seen fewer than 20 new cases per million people a day since mid-April. Palestine, meanwhile, faced a surge during March and April, with the territories’ highest COVID-19 case numbers yet.

While reported case numbers in Palestine have dropped in recent weeks, this is more likely due to a lack of testing than an actual drop in infections. And the situation is not improving. Though Israeli and Palestinian forces have now formally reached a cease-fire, Israeli police have continued to attack Palestinians—including an attack against worshippers at al-Aqsa Mosque.

Continued violence and lack of medical care for Palestinians may mean that the pandemic continues here long after it ends for Israel. As is true of all COVID-19 outbreaks, continued transmission may breed coronavirus variants that threaten the rest of the world.

More international reporting

  • We failed to vaccinate the world in 2021; will 2022 be more successful?
    In January, COVAX set a goal that many global health advocates considered modest: delivering 2.3 billion vaccine doses to low- and middle-income countries by the end of 2021. is saying it’ll deliver just 800 million vaccine doses by the end of 2021, according to the Washington Post, and only about 600 million had been delivered by early December.
  • Omicron variant: What we know, what we don’t, and why not to panic (yet)
    On Thanksgiving, my Twitter feed was dominated not by food photos, but by news of a novel coronavirus variant identified in South Africa earlier this week. While the variant—now called Omicron, or B.1.1.529—likely didn’t originate in South Africa, data from the country’s comprehensive surveillance system provided enough evidence to suggest that this variant could be more contagious than Delta, as well as potentially more able to evade human immune systems.
  • First COVID-19 antiviral pill gains authorization
    This week, an antiviral pill for COVID-19 was authorized in the U.K. The drug, made by American pharmaceutical company Merck, is the first COVID-19 treatment in pill form to gain approval by any regulatory agency.
  • Unpacking Delta AY.4.2: Are we prepared for the next variant?
    Recently, a new offshoot of the Delta variant has been gaining ground in the U.K. It’s called AY.4.2, and it appears to be slightly more transmissible than Delta itself. While experts say this variant doesn’t differ enough from Delta to pose a serious concern, I think it’s worth exploring what we know about it so far—and what this means for the future of coronavirus mutation.
  • Booster shots exacerbate global vaccine inequity
    At the end of last week’s post on booster shots, I wrote that these additional doses take up airtime in expert discussions and in the media, distracting from discussions of what it will take to vaccinate the world. But these shots do more harm than just taking over the media cycle. When the U.S. and other wealthy nations decide to give many residents third doses, they jump the vaccine supply line again—leaving low-income nations to wait even longer for first doses.

Leave a Reply